In Managed Healthcare Executive, Precision Oncology Chief Medical Officer Dr. Gerry Messerschmidt discusses the many recent advances in treating multiple myeloma.Innovative strategies and combinations of approved and experimental therapies have a high likelihood of gaining approval and becoming standard use. “This means more therapy, more often—and thus, potential financial ramifications for payers of myeloma treatment,” Messerschmidt said.
To read the complete Q&A, please click here.